^Mogler L, Franz F, Wilde M, Huppertz LM, Halter S, Angerer V, et al. (September 2018). "Phase I metabolism of the carbazole-derived synthetic cannabinoids EG-018, EG-2201, and MDMB-CHMCZCA and detection in human urine samples". Drug Testing and Analysis. 10 (9): 1417–1429. doi:10.1002/dta.2398. PMID29726116.
^Banister SD, Connor M (August 2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. Springer International Publishing. pp. 191–226. doi:10.1007/164_2018_144. ISBN978-3-030-10561-7. PMID30105473 – via Springer Link.
^Gaunitz F, Dahm P, Mogler L, Thomas A, Thevis M, Mercer-Chalmers-Bender K (June 2019). "In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and Cunninghamella elegans and their detection in urine samples". Analytical and Bioanalytical Chemistry. 411 (16): 3561–3579. doi:10.1007/s00216-019-01837-8. PMID31183523. S2CID184487406.
^Diao X, Carlier J, Zhu M, Huestis MA (July 2018). "Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology. 36 (2): 304–312. doi:10.1007/s11419-018-0404-2. ISSN1860-8973. S2CID44196013.